<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Excessive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> may have a role in the ineffective hematopoiesis and cytopenias observed in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The goals of this study were 1) to quantify <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in patients with "early stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> [including patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), RA with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), RA with excess blasts and with less than 10% blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(&lt;10))], and in patients with "late stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> [including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> with more than 10% blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(&gt;10)), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t), and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> secondary to <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (LAM2)]; 2) to study the activation of the caspase-3/CPP32 enzyme, a major "effector" caspase in hematopoiesis, in patients with "early stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, and 3) to evaluate the effect of caspase inhibition on the apoptotic phenotype and clonogenicity of hematopoietic progenitors in vitro in these patients </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: Patients: Fifty-four patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, including 30 with "early stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and 24 with "late stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> were studied </plain></SENT>
<SENT sid="3" pm="."><plain>Study of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>: TUNEL assay performed on bone marrow smears and/or quantification of annexin V positive bone marrow mononuclear cells by flow cytometric analysis </plain></SENT>
<SENT sid="4" pm="."><plain>Caspacse-3/CPP32 activity: Quantitative measurement of caspase-3/CPP32 activity on total bone marrow mononuclear cells using a fluorogenic substrate </plain></SENT>
<SENT sid="5" pm="."><plain>Effect of the caspase-inhibitor Z-VAD-FMK: 1) on the apoptotic phenotype of total bone marrow mononuclear cells and 2) on the clonogenicity of hematopoietic progenitor cells </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The group of 30 patients with "early stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> had statistically <z:mp ids='MP_0006042'>increased apoptosis</z:mp> compared to the group of 24 patients with "late stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (44.1% +/- 4.8 vs 21.8% +/- 3.6; p = 0.02) using the TDT-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick-end labeling (TUNEL) assay </plain></SENT>
<SENT sid="7" pm="."><plain>In the group of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>&lt;10) had excessive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> compared to those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>&gt;10) (44.0% +/- 3.5% vs 29.5% +/- 3.6%;p = 0.042) The median caspase-3 activity in 20 "early stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> patients was 19,000 U (range 3,460-41,000) and significantly increased compared to <z:mpath ids='MPATH_458'>normal</z:mpath> individuals (4,256 U, range 3,200-5,200; p = 0.032) Bone marrow mononuclear cells from 12 "early stage" <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (including 11 from the 20 studied for caspase-3 activity) were incubated with or without the broad-spectrum caspase inhibitor Z-VAD-FMK </plain></SENT>
<SENT sid="8" pm="."><plain>In 4 of 9 evaluable patients (44.4%) with excessive <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, the number of annexin V positive cells decreased in a dose-dependent manner in the presence of Z-VAD-FMK </plain></SENT>
<SENT sid="9" pm="."><plain>However, in none of these patients was caspase inhibition with Z-VAD-FMK able to enhance colony formation in vitro </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: These results confirm that a major characteristic of patients with "early stage" <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> is <z:mp ids='MP_0006042'>increased apoptosis</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>The results also indicate that excessive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in these patients is accompanied by increased caspase-3/CPP32 activity </plain></SENT>
<SENT sid="12" pm="."><plain>However, caspase inhibition with the broad-spectrum inhibitor Z-VAD-FMK cannot improve hematopoiesis in this group of patients, even when <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is attenuated </plain></SENT>
</text></document>